Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and a significant reported EBIT loss driven by the goodwill impairment announced in December. Accordingly, our view of the investment case remains intact, and we anticipate limited to no estimate revisions, alongside a modest share price reaction.
LÄS MER
